Patents by Inventor William FARNABY

William FARNABY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS DEGRADING COMPOUNDS COMPRISING ANNULATED 2-AMINO-3-CYANO THIOPHENES
    Publication number: 20250145608
    Abstract: The present invention relates to compounds and derivatives of formula (I) which target KRAS and can be useful as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: November 30, 2022
    Publication date: May 8, 2025
    Inventors: Joachim BROEKER, Jason ABBOTT, Alessio CIULLI, Jianwen CUI, Emelyne DIERS, William FARNABY, Stephen W. FESIK, Andreas GOLLNER, Jake GOODWIN-TINDALL, Tim HODGES, Christiane KOFINK, Andrew LITTLE, Andreas MANTOULIDIS, Ross MCLENNAN, Johannes POPOW, Dhruba SARKAR, Martin SCHMIEDEL, Christian Alan Paul SMETHURST, Nicole TRAINOR, Alex WATERSON, Harald WEINSTABL, Siying ZHONG, David ZOLLMAN
  • NOVEL TETRAHYDROQUINOLINES AND PROTEOLYSIS TARGETING CHIMERA (PROTACS) COMPRISING THEM AS DEGRADERS OF SMARCA
    Publication number: 20250049929
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups A, R1, R3 and R4 have the meanings given in the claims and specification, proteolysis targeting chimera (PROTACs) comprising such compounds of formula (I), their use as degraders of SMARCA, pharmaceutical compositions which contain PROTACs of this kind and their medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: September 27, 2022
    Publication date: February 13, 2025
    Inventors: Alessio CIULLI, Emelyne DIERS, William FARNABY, Peter GREB, Christiane KOFINK, Steffen STEURER, Nicole TRAINOR, Harald WEINSTABL
  • Proteolysis targeting chimera (PROTACS) as degraders of SMARCA2 and /or SMARCA4
    Patent number: 12187719
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1, A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: January 7, 2025
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessio Ciulli, Christian Dank, Emelyne Diers, William Farnaby, Michael Roy, Steffen Steurer, Nicole Trainor
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 12186313
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: January 7, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20220008416
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 30, 2021
    Publication date: January 13, 2022
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4
    Publication number: 20210380579
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1, A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 9, 2021
    Inventors: Alessio CIULLI, Christian DANK, Emelyne DIERS, William FARNABY, Michael ROY, Steffen STEURER, Nicole TRAINOR
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 11129828
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20200121678
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 23, 2020
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 10463663
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 5, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Amide derivatives as lysophosphatidic acid receptor antagonists
    Publication number: 20190010129
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 20, 2018
    Publication date: January 10, 2019
    Inventors: William Buffham, Hannah Canning, Richard Davenport, William Farnaby, Stephen Mack, Alka Parmar, Susanne Wright
  • Amide derivatives as lysophosphatidic acid receptor antagonists
    Patent number: 10100018
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: October 16, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Buffham, Hannah Canning, Richard Davenport, William Farnaby, Stephen Mack, Alka Parmar, Susanne Wright
  • Pyrimidinone compounds and their use
    Patent number: 10085986
    Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: October 2, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Xiao-Ling Fan Cockcroft, William Farnaby, Natasha Kinsella, Kevin Merchant, David Miller
  • 3-substituted 2-amino-indole derivatives
    Patent number: 10059713
    Abstract: The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X % X4, X5 X6, X7, R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 28, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Gregory Barker, Richard Davenport, Robert Downham, William Farnaby, Anne Goldby, Duncan Hannah, David Harrison, Henriette Willems
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20180177780
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 28, 2018
    Inventors: William FARNABY, Charlotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 9931340
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy:
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 3, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE
    Publication number: 20170369492
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Q, X4, X5, X6, X7, R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.
    Type: Application
    Filed: June 24, 2015
    Publication date: December 28, 2017
    Inventors: Richard DAVENPORT, Jonathan DUNN, William FARNABY, Duncan HANNAH, David HARRISON, Susanne WRIGHT
  • Pyridazinones as DAAO enzyme inhibitors
    Patent number: 9750748
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 5, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS
    Publication number: 20170173007
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 22, 2017
    Inventors: William FARNABY, CharLotte FIELDHOUSE, Katherine HAZEL, Catrina KERR, Natasha KINSELLA, David LIVERMORE, Kevin MERCHANT, David MILLER
  • 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES
    Publication number: 20170158700
    Abstract: The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X % X4, X5 X6, X7, R1, R2, R3 and R8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.
    Type: Application
    Filed: June 24, 2015
    Publication date: June 8, 2017
    Inventors: Gregory BARKER, Richard DAVENPORT, Robert DOWNHAM, William FARNABY, Anne GOLDBY, Duncan HANNAH, David HARRISON, Henriette WILLEMS
  • Compounds
    Patent number: 9464060
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: October 11, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Buffham, Hannah Canning, Richard Davenport, William Farnaby, Stephen Mack, Alka Parmar, Susanne Wright